Hyaluronic Acid Filler IMD1 Basic for Correction of Nasolabial Folds

Merz Pharmaceuticals logo

Merz Pharmaceuticals

Status and phase

Completed
Phase 4

Conditions

Nasolabial Folds

Treatments

Drug: Hyaluronic acid filler/IMD1 basic

Study type

Interventional

Funder types

Industry

Identifiers

NCT00429520
MRZ 90026-0423/1

Details and patient eligibility

About

Volunteers receive one injection IMD1 basic of correction of nasolabial folds and are followed-up for up to 36 weeks.

Sex

All

Ages

30 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

main inclusion criteria: severity rating scale grade 3 or 4

Exclusion criteria

main exclusion criterion: other nasolabial fold corrections within 6 months prior to study entry

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems